73 terminated. 73 Phase 2, 19 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 73 | Terminated 73 |
| Phase 1 | 19 | Terminated 19 |
| Phase 3 | 6 | Terminated 6 |
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). Active Comparator CT1812, Placebo Comparator - Age-Related Macular Degeneration | Phase 2 | Terminated | Cognition Therapeutics | 100 | 2023-06-16 | 2025-04-16 |
| Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa EA-2353 - Retinitis Pigmentosa, Retinitis Pigmentosa Syndrome | Phase 1 / Phase 2 | Terminated | Endogena Therapeutics, Inc | 14 | 2022-06-02 | 2024-10-15 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa RNA antisense oligonucleotide for intravitreal injection - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Terminated | Laboratoires Thea | 21 | 2021-09-16 | 2024-08-07 |
| A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Danicopan, Placebo - Geographic Atrophy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 365 | 2021-08-23 | 2025-09-05 |
| Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1 / Phase 2 | Terminated | AsclepiX Therapeutics, Inc. | 3 | 2021-02-01 | 2024-03-22 |
| A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration GEM103, Aflibercept, Sham - Neovascular Age-related Macular Degeneration, Retinal Disease | Phase 2 | Terminated | Gemini Therapeutics, Inc. | 50 | 2020-12-29 | 2022-10-31 |
| Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg - Diabetic Macular Edema (DME) | Phase 1 / Phase 2 | Terminated | AsclepiX Therapeutics, Inc. | 6 | 2020-12-10 | 2024-03-22 |
| A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Galegenimab - Macular Degeneration, Age-Related, Geographic Atrophy | Phase 2 | Terminated | Genentech, Inc. | 144 | 2020-11-16 | 2023-10-16 |
| HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 GT005 - Dry Age-related Macular Degeneration | Phase 2 | Terminated | Gyroscope Therapeutics Limited | 255 | 2020-09-28 | 2026-01-28 |
| A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration GEM103 - Dry Age-related Macular Degeneration, Geographic Atrophy | Phase 2 | Terminated | Gemini Therapeutics, Inc. | 62 | 2020-07-30 | 2022-09-23 |
| Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO) Hydroxychloroquine lower dose, Hydroxychloroquine higher dose - Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | University of Michigan | 8 | 2020-02-25 | 2024-10-26 |
| Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF intravitreal injection of Conbercept - Uveitis, Macular Edema | Phase 2 / Phase 3 | Terminated | Peking Union Medical College Hospital | 5 | 2019-10-12 | 2022-10-25 |
| A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. KSI-301, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 2 / Phase 3 | Terminated | Kodiak Sciences Inc | 559 | 2019-10-08 | 2024-07-18 |
| A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) Galegenimab, Sham Control - Macular Degeneration, Age-Related, Geographic Atrophy | Phase 2 | Terminated | Genentech, Inc. | 372 | 2019-06-03 | 2024-03-27 |
| EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 GT005 - Dry Age-related Macular Degeneration | Phase 2 | Terminated | Gyroscope Therapeutics Limited | 98 | 2019-04-26 | 2026-01-27 |
| A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration MT-0814, Placebo - Age-related Macular Degeneration | Phase 2 | Terminated | Senju Pharmaceutical Co., Ltd. | 13 | 2019-02-25 | 2021-04-20 |
| FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD GT005, GT005 / Device: Orbit™ Subretinal Delivery System - Dry Age-related Macular Degeneration, Macular Degeneration | Phase 1 / Phase 2 | Terminated | Gyroscope Therapeutics Limited | 56 | 2018-12-17 | 2026-01-28 |
| Carbidopa-Levodopa in Dry AMD With Geographic Atrophy carbidopa-levodopa - Age Related Macular Degeneration | Phase 2 | Terminated | Snyder, Robert W., M.D., Ph.D., P.C. | 7 | 2018-07-01 | 2024-04-25 |
Showing 20 of 73. Sign in to see all of them.
Macular Degeneration (43) · Macular Edema (16) · Retinal Diseases (14) · Eye Diseases (13) · Geographic Atrophy (13) · Choroidal Neovascularization (10) · Retinitis Pigmentosa (7) · Vision Disorders (5) · Usher Syndromes (4) · Uveitis (4) · Anetoderma (3) · Diabetes Mellitus (3) · Diabetic Retinopathy (3) · Eye Diseases, Hereditary (3)
Eye Diseases (60) · Retinal Diseases (59) · Macular Degeneration (23) · Pathological Conditions, Signs and Symptoms (16) · Eye Diseases, Hereditary (15) · Uveal Diseases (15) · Choroid Diseases (10) · Metaplasia (10) · Neovascularization, Pathologic (10) · Pathologic Processes (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (8) · Retinal Dystrophies (7) · Nervous System Diseases (6)
Ranibizumab (14) · Bevacizumab (6) · aflibercept (5) · salicylhydroxamic acid (5) · Intravitreal Injections (4) · Sirolimus (3) · squalamine lactate (3) · AXT107 (2) · Calcium Dobesilate (2) · Dexamethasone (2) · Fluocinolone Acetonide (2) · pegaptanib (2) · 4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol (1) · Brimonidine Tartrate (1) · Everolimus (1)
National Eye Institute (NEI) (4) · Allergan (3) · Asociación para Evitar la Ceguera en México (3) · Genaera Corporation (3) · Genentech, Inc. (3) · Gyroscope Therapeutics Limited (3) · Laboratoires Thea (3) · Novartis Pharmaceuticals (3) · Pfizer (3) · Alcon Research (2) · Alimera Sciences (2) · AsclepiX Therapeutics, Inc. (2) · Gemini Therapeutics, Inc. (2) · Johns Hopkins University (2) · Merck Sharp & Dohme LLC (2)
United States (63) · France (12) · Germany (11) · United Kingdom (10) · Australia (7) · Poland (6) · Spain (6) · Czechia (5) · Hungary (4) · Italy (4) · Mexico (4) · Netherlands (4) · Israel (3) · Slovakia (3) · Austria (2)
Joel Naor, MD (3) · Amir Shojaei, PhD (2) · Hugo Quiroz-Mercado, MD (2) · Adrienne Scott, Doctor (1) · Alexander Eaton, MD (1) · Amy Schaberg, BSN (1) · Anne Fung, MD (1) · Anthony Caggiano (1) · Armen Mashayekhi, MD (1)
PMID 37314061, PMID 22424834, PMID 22828504, PMID 24705452, PMID 24896137, PMID 25079064, PMID 26857842, PMID 27730010, PMID 29847672, PMID 30194931, PMID 30646425, PMID 32134802, PMID 33383315, PMID 33750925, PMID 41747884, PMID 42518791
2014 (1), 2016 (1), 2019 (1)